ACKNOWLEDGMENT

The authors thank Dr. Brenda Banwell for bringing the American XMEA family, key to the progress in this work, to the attention of the corresponding author.

1. Nishino I. Autophagic vacuolar myopathy. *Semin Pediatr Neurol* 2006;13:90–95.
2. Nishino I, Fu J, Tanji K, et al. Primary LAMP-2 deficiency causes X-linked vacuolar cardiomyopathy and myopathy (Danon disease). *Nature* 2000;406:906–910.
3. Minassian B, Aiyar A, Alic S, et al. Narrowing in on the causative defect of an intriguing X-linked myopathy with excessive autophagy. *Neurology* 2002;59:596–601.
4. Kalimo H, Savontaus ML, Lang H, et al. X-linked myopathy with excessive autophagy: a new hereditary muscle disease. *Ann Neurol* 1988;23:258–265.
5. Villanova M, Louboutin JP, Chateau D, et al. X-linked vacuolated myopathy: complement membrane attack complex on surface membrane of injured muscle fibers. *Ann Neurol* 1995;37:637–645.
6. Jaaskelainen SK, Juel VC, Udd B, et al. Electrophysiological findings in X-linked myopathy with excessive autophagy. *Ann Neurol* 2002;51:648–652.
7. Munteanu I, Ackerley CA, Mnatzakanian GN, et al. Electrophysiology extends the phenotypic spectrum of X-linked myopathy with excessive autophagy. *Neurology* 2005;64:927–928.

CORRECTION

A 12-week, placebo-controlled study (6002-US-006) of istradefylline in Parkinson disease

In the article “A 12-week, placebo-controlled study (6002-US-006) of istradefylline in Parkinson disease” by M. Stacy et al. (*Neurology*® 2008;70:2233–2240), table 1 was inadvertently reprinted as table 2. The primary outcome data for this double-blind, placebo-controlled initiative were omitted. The publisher regrets the error. The correct Table 2 is shown below:

Table 2 Least squares mean difference from placebo for the change from baseline to endpoint (intent-to-treat population)

	Istradefylline 20 mg/day, n = 163, vs placebo, n = 77	Istradefylline 60 mg/day, n = 155, vs placebo, n = 77	Overall p value*
24-h ON/OFF subject diary data			
Time spent in OFF state, %	−4.35, p=0.026†	−4.49, p=0.024†	0.049
Total hours	−0.64	−0.77	0.065
Time spent in ON state without dyskinesia, %	1.30	3.03	0.540
Total hours	0.25	0.46	0.628
Time spent in ON state with dyskinesia, %	2.52	1.40	0.598
Total hours	0.54	0.23	0.413
Time spent in ON state with nontroublesome	2.33	0.95	0.513
Total hours	0.53	0.18	0.272
Time spent in ON state with troublesome dyskinesia, %	0.40	0.30	0.955
Total hours	0.06	0.04	0.964
Time spent in ON state without troublesome dyskinesia, %	3.52	4.04	0.168
Total hours	0.71	0.60	0.161
Unified Parkinson's Disease Rating Scale evaluations			
Subscale III, rated in OFF state	−0.99	−1.28	0.491
Subscale III, rated in ON state	−0.30	−0.87	0.553

*Overall p value—based F test with 2 degrees of freedom.

†p Value for individual comparisons (istradefylline groups vs placebo group).

Neurology®

CORRECTION

Neurology 2008;71;953

DOI 10.1212/01.wnl.0000335326.54243.b7

This information is current as of September 15, 2008

Updated Information & Services

including high resolution figures, can be found at:
<http://n.neurology.org/content/71/12/953.full>

Permissions & Licensing

Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at:
http://www.neurology.org/about/about_the_journal#permissions

Reprints

Information about ordering reprints can be found online:
<http://n.neurology.org/subscribers/advertise>

Neurology® is the official journal of the American Academy of Neurology. Published continuously since 1951, it is now a weekly with 48 issues per year. Copyright . All rights reserved. Print ISSN: 0028-3878. Online ISSN: 1526-632X.